Drug news
Generic Exelon patch (rivastigmine transdermal system) for dementia in Alzheimers and Parkinsons disease launched in US-Alvogen
Alvogen has launched the first generic equivalent of Exelon patch (rivastigmine transdermal system) in the United States. The product will be marketed by Alvogen in three strengths (4.6 mg/24 hours, 9.5 mg/24 hours, and 13.3 mg/24 hours) with Alvogen being the first filer for the 13.3 mg/24 hours strength, making it eligible for 180 days of marketing exclusivity. The product is indicated for mild to moderate dementia in Parkinsons disease and Alzheimers disease.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins